2018
High prevalence of non-adherence to antiretroviral therapy among undisclosed HIV-infected children in Ghana
Nichols JS, Kyriakides TC, Antwi S, Renner L, Lartey M, Seaneke OA, Obeng R, Catlin AC, Gan G, Reynolds NR, Paintsil E, Team O. High prevalence of non-adherence to antiretroviral therapy among undisclosed HIV-infected children in Ghana. AIDS Care 2018, 31: 25-34. PMID: 30235940, PMCID: PMC6288009, DOI: 10.1080/09540121.2018.1524113.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyART adherence ratesPediatric HIV carePrevalence of adherenceAntiretroviral medication adherenceCohort of childrenHIV-positive statusChildren of caregiversChild-caregiver dyadsHIV carePharmacy recordsRefill dataMedian adherenceMedication adherenceAdherence ratesPoor adherenceHigh prevalencePositive statusIntervention studiesHIVGood adherenceAdherenceBaseline dataChildrenTherapy
2013
Progressive Increase in Cerebrospinal Fluid (CSF) Neopterin and Relation to Neuropsychological Performance during Primary HIV-1 Infection Prior to Antiretroviral Therapy (P06.189)
Suh J, Robertson K, Peterson J, Lee E, Kyriakides T, Li F, Fuchs D, Price R, Hagberg L, Gisslen M, Spudich S. Progressive Increase in Cerebrospinal Fluid (CSF) Neopterin and Relation to Neuropsychological Performance during Primary HIV-1 Infection Prior to Antiretroviral Therapy (P06.189). Neurology 2013, 80 DOI: 10.1212/wnl.80.7_supplement.p06.189.Peer-Reviewed Original Research
2011
Effect of Treatment Interruption and Intensification of Antiretroviral Therapy on Health-Related Quality of Life in Patients with Advanced HIV
Joyce VR, Barnett PG, Chow A, Bayoumi AM, Griffin SC, Sun H, Holodniy M, Brown ST, Kyriakides TC, Cameron DW, Youle M, Sculpher M, Anis AH, Owens DK. Effect of Treatment Interruption and Intensification of Antiretroviral Therapy on Health-Related Quality of Life in Patients with Advanced HIV. Medical Decision Making 2011, 32: 70-82. PMID: 21383086, DOI: 10.1177/0272989x10397615.Peer-Reviewed Original ResearchConceptsVisual analog scaleHIV patientsART intensificationTreatment interruptionClinical eventsMedical Outcomes Study HIV Health SurveyAdvanced HIV patientsAntiretroviral therapy interruptionMultiple treatment failuresTemporary treatment interruptionAdverse clinical eventsHealth-related qualityStandard ARTHealth Utilities IndexStandard gambleQuality of lifeAdvanced HIVART interruptionInferior HRQoLMDR HIVTherapy interruptionAntiretroviral therapyHIV cohortOpen labelHRQoL scores
2003
An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial
Kyriakides TC, Babiker A, Singer J, Cameron W, Schechter MT, Holodniy M, Brown ST, Youle M, Gazzard B, Team O. An open-label randomized clinical trial of novel therapeutic strategies for HIV-infected patients in whom antiretroviral therapy has failed: rationale and design of the OPTIMA Trial. Contemporary Clinical Trials 2003, 24: 481-500. PMID: 12865041, DOI: 10.1016/s0197-2456(03)00029-1.Peer-Reviewed Original ResearchConceptsOPTIMA trialClinical trialsTherapeutic strategiesHuman immunodeficiency virus-infected individualsVirus-infected individualsDrug-free periodVeterans Affairs hospitalDifferent therapeutic strategiesYears of intakeNovel therapeutic strategiesAnti-HIV drugsAntiretroviral therapyStrategy armART drugsTrial designHIV drugsStudy durationHospitalTrialsRelative efficacyDrugsTherapyOptimum trial designYearsMulticenter
2001
Development and Application of a Genotypic AZT Resistance Assay
Kyriakides T, Heimer R. Development and Application of a Genotypic AZT Resistance Assay. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 211-220. DOI: 10.1097/00126334-200111010-00002.Peer-Reviewed Original ResearchViral loadCD4 countAZT resistanceResistance indexResistance profilesBaseline viral loadHIV disease progressionLigase chain reaction assayMonths of treatmentResistance assaysAntiretroviral therapyDisease progressionSurrogate markerChain reaction assaysHIV-1PatientsAZTPredictive abilityReaction assaysCountAssaysFurther supportIndexAntiretroviralsHIVDevelopment and Application of a Genotypic AZT Resistance Assay: Quantitative Assessment of the Resistance Profile of Clinical Samples and the Relative Predictive Ability of a Resistance Index.
Kyriakides TC, Heimer RR. Development and Application of a Genotypic AZT Resistance Assay: Quantitative Assessment of the Resistance Profile of Clinical Samples and the Relative Predictive Ability of a Resistance Index. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 211. PMID: 11694826, DOI: 10.1097/00042560-200111010-00002.Peer-Reviewed Original ResearchConceptsViral loadCD4 countResistance indexAZT resistanceResistance profilesBaseline viral loadHIV disease progressionLigase chain reaction assayMonths of treatmentWild-type HIV-1Resistance assaysAntiretroviral therapyDisease progressionSurrogate markerChain reaction assaysHIV-1PatientsAZTPredictive abilityClinical samplesReaction assaysCountAssaysRelative predictive abilityFurther support